

**Brilliant Violet 421™ anti-mouse/human CD11b**

**Catalog # / Size:** 1106180 / 500 µl  
1106175 / 125 µl  
  
1106255 / 50 µg

**Clone:** M1/70

**Isotype:** Rat IgG2b, κ


**Immunogen:** C57BL/10 splenocytes

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** microg sizes: 0.2 mg/ml  
microL sizes: lot-specific



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 421™ (filled histogram) or rat IgG2b, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.


**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. For flow cytometric staining using the microL sizes, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be



BL/6 mouse lymph nodes, fixed O/N in PLP, blocked with 10% rat serum, stained with CD11b-BV421™ (red), B220-Alexa Fluor® 647 (blue), CD14-FITC (green) in 1% BSA and 0.1% Tween-20 in PBS. Images were acquired with an automated widefield microscope.

resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for relevant formats of this clone) include: immunoprecipitation<sup>1,4</sup>, *in vitro* blocking<sup>3,9,12</sup>, depletion<sup>2,8</sup>, immunofluorescence microscopy<sup>6,7,10</sup>, and immunohistochemistry of acetone-fixed frozen sections<sup>5,11-13</sup> and paraffin sections<sup>28</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 101231). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101248) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

- Application References:**
1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
  2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
  3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
  4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
  5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
  6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
  7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
  8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
  9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
  11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
  12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
  14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
  15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
  16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
  17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
  18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
  19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
  20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
  21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
  22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
  23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
  24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
  25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
  26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
  27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
  29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
  30. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
  31. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)

---

**Description:** CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

**Antigen References:**

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. *Cell* 76:301.

3. Coxon A, *et al.* 1996. *Immunity* 5:653.